S100A9 and hepatocellular carcinoma: A recent study found that the selective β2‐blocker ICI‐118551 inhibited norepinephrine‐mediated secretion of S100A8/A9 and that inhibition of S100A9 by Tas or ICI‐118551 abrogated stress‐induced reactivation of dormant tumor cells.[25] Consistently,[26] we noticed that selective β2‐blockers, but not selective β1‐blockers, could also inhibit the lung metastasis of HCC in vitro, raising the possibility that combining β2‐blockers or nonselective β blockers with TACE might benefit HCC patients.